Pharmacogenetic-based strategy using de novo tacrolimus once daily after kidney transplantation: prospective pilot study

2016 ◽  
Vol 17 (9) ◽  
pp. 1019-1027 ◽  
Author(s):  
Martine De Meyer ◽  
Vincent Haufroid ◽  
Nada Kanaan ◽  
Tom Darius ◽  
Antoine Buemi ◽  
...  
2018 ◽  
Vol 32 (8) ◽  
pp. e13311 ◽  
Author(s):  
Petra Glander ◽  
Johannes Waiser ◽  
Silke Kasbohm ◽  
Frank Friedersdorff ◽  
Robert Peters ◽  
...  

2010 ◽  
Vol 42 (4) ◽  
pp. 1308-1311 ◽  
Author(s):  
E. Favi ◽  
G. Spagnoletti ◽  
A. Gargiulo ◽  
M.P. Salerno ◽  
J. Romagnoli ◽  
...  

2020 ◽  
Vol 34 (8) ◽  
Author(s):  
Rachel C. Forbes ◽  
Beatrice P. Concepcion ◽  
Deana Clapper ◽  
Bernard J. DuBray ◽  
Saed Shawar ◽  
...  

10.2196/14622 ◽  
2019 ◽  
Vol 8 (10) ◽  
pp. e14622 ◽  
Author(s):  
Franziska Alexandra Meister ◽  
Zoltan Czigany ◽  
Jan Bednarsch ◽  
Jörg Böcker ◽  
Iakovos Amygdalos ◽  
...  

Background Kidney transplantation is the only curative treatment option for end-stage renal disease. The unavailability of adequate organs for transplantation has resulted in a substantial organ shortage. As such, kidney donor allografts that would have previously been deemed unsuitable for transplantation have become an essential organ pool of extended criteria donor allografts that are now routinely being transplanted on a global scale. However, these extended criteria donor allografts are associated with significant graft-related complications. As a result, hypothermic oxygenated machine perfusion (HOPE) has emerged as a powerful, novel technique in organ preservation, and it has recently been tested in preclinical trials in kidney transplantation. In addition, HOPE has already provided promising results in a few clinical series of liver transplantations where the liver was donated after cardiac death. Objective The present trial is an investigator-initiated prospective pilot study on the effects of HOPE on extended criteria donor allografts donated after brain death and used in kidney transplantation. Methods A total of 15 kidney allografts with defined inclusion/exclusion criteria will be submitted to two hours of HOPE via the renal artery before implantation, and are going to be compared to a case-matched group of 30 patients (1:2 matching) who had kidneys transplanted after conventional cold storage. Primary (posttransplant dialysis within 7 days) and secondary (postoperative complications, early graft function, duration of hospital and intensive care unit stay, and six-month graft survival) endpoints will be analyzed within a six-month follow-up period. The extent of ischemia-reperfusion injury will be assessed using kidney tissue, perfusate, and serum samples taken during the perioperative phase of kidney transplantation Results The results of this trial are expected in the first quarter of 2020 and will be presented at national and international scientific meetings and published in international peer-reviewed medical journals. The trial was funded in the third quarter of 2017 and patient enrollment is currently ongoing. Conclusions This prospective study is designed to explore the effects of HOPE on extended criteria donor kidney allografts donated after brain death. The present report represents the preresults phase. Trial Registration Clinicaltrials.gov NCT03378817; https://clinicaltrials.gov/ct2/show/NCT03378817


Author(s):  
René Koning ◽  
Charles Chan ◽  
Hélène Eltchaninoff ◽  
Christophe Tron ◽  
Satej Janorkar ◽  
...  

2004 ◽  
Vol 9 (3) ◽  
pp. 198-201
Author(s):  
Claire E. Cuttica ◽  
Michael F. Chicella ◽  
Dawn E. Butler ◽  
Ajay Kaul

This study compared the safety and efficacy of enterally administered pantoprazole, omeprazole and ranitidine at raising gastric pH above 4 in children with gastroesophageal reflux disease. Children with gastrostomy tubes that were being treated with one of the three drugs were included. Caregivers were taught to measure gastric pH. Dose, time of last meal, time of last dose, and time of gastric pH were collected. Four weekly pH measurements were compared among the groups. Seventeen patients were enrolled. Six received ranitidine, 6 received omeprazole, and 5 received pantoprazole. Mean doses were: ranitidine 6.8 mg/kg/day, omeprazole 1.4 mg/kg/day and pantoprazole 1.3 mg/kg/day. Mean gastric pH was 3, 4.3, and 4 for the ranitidine, omeprazole and pantoprazole groups, respectively. Twenty-nine percent of pH readings in the ranitidine, 66% in the omeprazole, and 60% in the pantoprazole group were above 4. Comparing pH to time since last dose, ranitidine failed to routinely achieve pH > 4. Pantoprazole and omeprazole achieved this, but by 12 hours after the dose both failed to maintain pH > 4. Pantoprazole and omeprazole appear more effective at controlling gastric pH than ranitidine. Pantoprazole appears safe, however doses of 1–1.5 mg/kg/day once daily may not be effective in maintaining gastric pH > 4 in children with GERD.


2019 ◽  
Author(s):  
Franziska Alexandra Meister ◽  
Zoltan Czigany ◽  
Jan Bednarsch ◽  
Jörg Böcker ◽  
Iakovos Amygdalos ◽  
...  

BACKGROUND Kidney transplantation is the only curative treatment option for end-stage renal disease. The unavailability of adequate organs for transplantation has resulted in a substantial organ shortage. As such, kidney donor allografts that would have previously been deemed unsuitable for transplantation have become an essential organ pool of extended criteria donor allografts that are now routinely being transplanted on a global scale. However, these extended criteria donor allografts are associated with significant graft-related complications. As a result, hypothermic oxygenated machine perfusion (HOPE) has emerged as a powerful, novel technique in organ preservation, and it has recently been tested in preclinical trials in kidney transplantation. In addition, HOPE has already provided promising results in a few clinical series of liver transplantations where the liver was donated after cardiac death. OBJECTIVE The present trial is an investigator-initiated prospective pilot study on the effects of HOPE on extended criteria donor allografts donated after brain death and used in kidney transplantation. METHODS A total of 15 kidney allografts with defined inclusion/exclusion criteria will be submitted to two hours of HOPE via the renal artery before implantation, and are going to be compared to a case-matched group of 30 patients (1:2 matching) who had kidneys transplanted after conventional cold storage. Primary (posttransplant dialysis within 7 days) and secondary (postoperative complications, early graft function, duration of hospital and intensive care unit stay, and six-month graft survival) endpoints will be analyzed within a six-month follow-up period. The extent of ischemia-reperfusion injury will be assessed using kidney tissue, perfusate, and serum samples taken during the perioperative phase of kidney transplantation RESULTS The results of this trial are expected in the first quarter of 2020 and will be presented at national and international scientific meetings and published in international peer-reviewed medical journals. The trial was funded in the third quarter of 2017 and patient enrollment is currently ongoing. CONCLUSIONS This prospective study is designed to explore the effects of HOPE on extended criteria donor kidney allografts donated after brain death. The present report represents the preresults phase. CLINICALTRIAL Clinicaltrials.gov NCT03378817; https://clinicaltrials.gov/ct2/show/NCT03378817


2018 ◽  
Vol 32 (12) ◽  
pp. e13423
Author(s):  
Masayoshi Okumi ◽  
Kohei Unagami ◽  
Miyuki Furusawa ◽  
Yoichi Kakuta ◽  
Junpei IIzuka ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document